文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

PSMA-PET与机器学习优化前列腺癌挽救放疗预后分层

Refining prognostic stratification in salvage radiotherapy for prostate cancer: a retrospective multicenter cohort study using PSMA-PET and machine learning.
PubMed 文献 · Radiother Oncol · 2025-08-21

这项回顾性多中心队列从1201例中选取255例根治性前列腺切除术后生化复发且PSMA-PET阴性的患者,接受挽救放疗,中位随访33个月,2年生化无复发生存率为88.2%。CART分析显示PSMA-PET结果在PSA<0.2 ng/mL患者中显著影响预后,而PSA倍增时间在PSA 0.2-0.5 ng/mL患者中具有预测价值;挽救放疗剂量和 elective 淋巴结照射未显著影响bRFS。

要点

  • PSA<0.2 ng/mL时PSMA-PET结果显著影响预后。
  • PSA 0.2-0.5 ng/mL时PSA倍增时间具有预测价值。
  • 挽救放疗剂量与 elective 淋巴结照射未显著影响bRFS。

核心结论

  • PSMA-PET与CART分析有助于前列腺癌挽救放疗的细化风险分层。

研究设计与样本

  • 回顾性多中心队列研究,从1201例数据库中选取11个中心的255例接受挽救放疗的患者。

主要发现

  • 中位随访33个月,2年bRFS为88.2%。
  • PSA<0.2 ng/mL、PSMA-PET阴性、较长的PSA倍增时间、较大年龄、ISUP分级1-2及手术至生化复发间隔较短与改善的bRFS相关。
  • CART分析显示PSMA-PET结果在PSA<0.2 ng/mL患者中显著影响预后。
  • CART分析显示PSA倍增时间在PSA 0.2-0.5 ng/mL患者中具有预测价值。
  • 挽救放疗剂量和 elective 淋巴结照射未显著影响bRFS。

关键数值与推荐

  • 纳入标准:根治性前列腺切除术后PSA持续或复发≥0.1 ng/mL,且PSMA-PET阴性(无淋巴结或远处转移)。
  • 排除标准:接受雄激素剥夺治疗或挽救放疗前PSA>0.5 ng/mL。

临床怎么用

  • 对挽救放疗前PSA<0.2 ng/mL的患者,可结合PSMA-PET结果进行风险分层。
  • 对挽救放疗前PSA 0.2-0.5 ng/mL的患者,可参考PSA倍增时间评估预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salvage radiotherapy (SRT) is the standard treatment for biochemical recurrence (bREC) after radical prostatectomy (RP), yet optimal radiation dose, field size, and the role of advanced imaging like PSMA-PET remain unclear. This study assessed the impact of SRT dose and the prognostic role of PSMA-PET on 2-year biochemical relapse-free survival (bRFS) in patients with localized disease. METHODS: In this retrospective multicenter study, 255 patients treated with SRT across 11 centers were selected from a database of 1,201 cases. Inclusion criteria included PSA persistence/recurrence (≥0.1 ng/mL) post-RP and negative PSMA-PET for nodal or distant metastases. Patients receiving androgen deprivation therapy or with PSA > 0.5 ng/mL pre-SRT were excluded. Prognostic factors were identified using LASSO analysis and modeled with CART analysis. The primary endpoint was 2-year bRFS. RESULTS: With a median follow-up of 33 months, 2-year bRFS was 88.2 %. Lower pre-SRT PSA (<0.2 ng/mL), PSMA-PET negativity, longer PSA doubling time, older age, favorable ISUP grades (1-2), and shorter intervals from surgery to bREC were associated with improved bRFS. CART analysis demonstrated that PSMA-PET findings significantly influenced prognosis in patients with PSA levels below 0.2 ng/mL, while PSA-doubling time was predictive in patients with PSA 0.2-0.5 ng/mL. SRT dose and elective nodal irradiation did not significantly affect bRFS. CONCLUSIONS: This study underscores the complexity of prognostic modeling in SRT for prostate cancer, highlighting the value of PSMA-PET and CART for refined risk stratification.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Medici F, Aebersold DM, Casuscelli J, et al. Refining prognostic stratification in salvage radiotherapy for prostate cancer: a retrospective multicenter cohort study using PSMA-PET and machine learning. Radiother Oncol. 2025. PMID: 40849083. doi:10.1016/j.radonc.2025.111113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。